January 16, 2024 02:54 PM EST

A decade after its first FDA approval, Takeda expands label of HyQvia to include rare autoimmune disorder

Zachary Brennan

Senior Editor

The FDA on Monday extended the label for Takeda’s HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) as a maintenance therapy to prevent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A decade after its first FDA approval, Takeda expands label of HyQvia to include rare autoimmune disorder

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

A decade af­ter its first FDA ap­proval, Take­da ex­pands la­bel of HyQvia to in­clude rare au­toim­mune dis­or­der

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A decade after its first FDA approval, Takeda expands label of HyQvia to include rare autoimmune disorder

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings